Update in the treatment of extracranial atherosclerotic disease for stroke prevention. by Zhu, Zhu & Yu, Wengui
UC Irvine
UC Irvine Previously Published Works
Title
Update in the treatment of extracranial atherosclerotic disease for stroke prevention.
Permalink
https://escholarship.org/uc/item/13d104ds
Journal
Stroke and vascular neurology, 5(1)
ISSN
2059-8688
Authors
Zhu, Zhu
Yu, Wengui
Publication Date
2020
DOI
10.1136/svn-2019-000261
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
   65Zhu Z, Yu W. Stroke & Vascular Neurology 2020;5:e000261. doi:10.1136/svn-2019-000261
Open access 
Update in the treatment of extracranial 
atherosclerotic disease for 
stroke prevention
Zhu Zhu  ,1,2 Wengui Yu  1
1Department of Neurology, 
University of California Irvine, 
Irvine, California, USA
2Department of Neurology, 
Huashan Hospital Fudan 
University, Shanghai, China
Correspondence to
Dr Wengui Yu, Department 
of Neurology, University of 
California, Manchester, CA 9286, 
USA;  wyu@ uci. edu
To cite: Zhu Z, Yu W. Update in 
the treatment of extracranial 
atherosclerotic disease for 
stroke prevention. Stroke & 
Vascular Neurology 2020;5: 
e000261. doi:10.1136/svn-
2019-000261
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ svn- 
2019- 000261).
Received 14 July 2019
Revised 10 October 2019
Accepted 28 October 2019
Published Online First 
7 November 2019
Review
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY. 
Published by BMJ.
AbsTrACT
Stroke is a leading cause of adult mortality and 
disability worldwide. Extracranial atherosclerotic disease 
(ECAD), primarily, carotid artery stenosis, accounts 
for approximately 18%–25% of ischaemic stroke. 
Recent advances in neuroimaging, medical therapy and 
interventional management have led to A significant 
reduction of stroke from carotid artery stenosis. The 
current treatment of ECAD includes optimal medical 
therapy, carotid endarterectomy (CEA) and carotid artery 
stenting (CAS). The selection of treatments depends 
on symptomatic status, severity of stenosis, individual 
factors, efficacy and risk of complications. The aim of this 
paper is to review current evidence and guidelines on 
the management of carotid artery stenosis, including the 
comparison of medical and interventional therapy (CAS and 
CEA), as well as future directions.
InTroduCTIon
Stroke is the leading cause of adult mortality 
and disability worldwide. Extracranial ather-
osclerotic disease (ECAD), primarily, carotid 
artery stenosis, accounts for approximately 
18%–25% of ischaemic stroke.1 2 ECAD can 
be managed with optimal medical therapy 
(OMT), carotid endarterectomy (CEA), and 
carotid artery stenting (CAS). Treatment 
options largely depend on the presence of 
symptoms, severity of stenosis, individual 
factors, efficacy and risk of complications.
sympToms And severITy of CAroTId sTenosIs
Symptomatic carotid artery stenosis is defined 
as focal neurological symptoms that are 
sudden in onset and referable to ipsilateral 
carotid atherosclerotic pathology, including 
one or more transient ischaemic attack (TIA) 
or ischaemic stroke within the previous 6 
months.3 The risk of recurrent ipsilateral 
stroke in patients with symptomatic moderate 
to severe carotid stenosis varies from 2.7% 
within the first day to 18.8% within 90 days 
after symptoms onset,4 significantly higher 
than those with asymptomatic stenosis with 
annual risk of stroke ranging from 0.34% to 
2%.5 Despite conflicting results on the asso-
ciation between severity of carotid artery 
stenosis and risk of stroke,4 6 linear corre-
lation between the benefit from CEA and 
degree of stenosis has been confirmed by 
previous research. Data of 6092 patients 
with 35 000 patient- years of follow- up showed 
that the absolute risk reduction (ARR) 
from CEA was −2.2% in patients with <30% 
stenosis, 3.2% with 30%–49% stenosis, 4.6% 
with 50%–69% stenosis and 16.0% with 
70%–99% stenosis.7 Therefore, the presence 
of symptoms and severity of stenosis serve as 
main factors for selection of treatment.
IndIvIduAl fACTors
Age
Subgroup analysis of Carotid Revascularisa-
tion Endarterectomy vs Stent Trial (CREST) 
showed increased periprocedural stroke/MI/
death by 1.77 times in patients older than 70 
years treated with CAS, whereas no evidence 
of increased risk in CEA- treated patients.8 
A meta- analysis of 4 randomised controlled 
trials (RCTs) also demonstrated significantly 
increased risk of stroke or death within 30 
days after CAS in patients older than 70 and 
80 years of age compared with those under 60 
years of age (OR, 4.01 and 4.15, respectively).9 
This association, however, was not found 
in patients undergoing CEA. Notably, even 
though CEA may be generally preferable to 
CAS in patients over 70 years old due to lower 
periprocedural rate of stroke or death,9 CAS 
is a reasonable choice in elderly patients with 
unfavourable anatomy for CEA, radiation- 
induced stenosis or restenosis after CEA.
Gender
Pooled data from ECST (European Carotid 
Surgery Trial) and NASCET (North Amer-
ican Symptomatic Carotid Endarterectomy 
Trial) found greater benefit from surgery 
in men with the number needed to treat to 
prevent ipsilateral stroke in 5 years being 9 
for men vs 36 for women in patients with 50% 
or higher stenosis.9 In addition, the 30- day 
perioperative risk of death was significantly 
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higher in women than in men (2.3% vs 0.8%, p=0.002).10 
Combined analysis of NASCET and the ASA and Carotid 
Endarterectomy (ACE) trial found no benefit from 
CEA in women (ARR=3.0%, p=0.94), contrary to men 
(ARR=10.0%, p=0.02) in 50%–69% carotid stenosis. 
In contrast, with 70% to 99% stenosis, CEA was benefi-
cially in both men and women with similar 5- year ARR in 
stroke (17.3% vs 15.1%).10 Therefore, CEA is effective for 
stroke prevention in symptomatic severe carotid stenosis 
(≥70%) regardless of genders, while may be only benefi-
cial in men and selected women (eg, high risk of stroke) 
with moderate stenosis (50%–69%).
lesion features
Signs of unstable plaques—including rapidly progressing 
lesions, intraplaque haemorrhage, irregular/ulcerated 
surface, inflammation and microvascularization—have 
been increasingly reported as an independent predictor 
of stroke.1 11–14 Latest European Society of Cardiology 
(ESC) guideline also recommends targeting revasculari-
sation in a subgroup of patients with risky clinical and/
or imaging features, including ipsilateral silent infarction, 
stenosis progression, large plaques, echolucent plaques, 
lipid- rich necrotic core and so on.15
bilateral carotid stenosis
Various degrees of bilateral carotid stenosis are not rare in 
patients with atherosclerotic disease. For severe stenosis, 
staged rather than simultaneous approach is recom-
mended due to risks of respiratory failure or fluctuating 
blood pressure.16 If surgery is indicated, then the sympto-
matic side is generally treated first. For bilateral asympto-
matic stenosis, more severe stenosis is recommended to 
be addressed first. If the degree of stenosis is similar on 
both sides, then the artery supplying the dominant hemi-
sphere can be considered for treatment first. Analysis of 
NASCET showed higher periprocedural complications 
of CEA in patients with contralateral carotid occlusion,17 
while the outcome after CAS seemed to be less affected 
according to a review of 1375 patients.18
Tandem lesions
The reported prevalence of stenosis of the internal 
carotid artery and ipsilateral common carotid is 4.3%.19 
Treatment of tandem lesions is challenging with up to 
20% perioperative mortality rate with CEA.20 Hybrid 
repair comprising CEA of the carotid bifurcation and 
retrograde endovascular repair of common carotid artery 
has been frequently reported with lower combined stroke 
and death rate than CEA alone.21 Research with a small 
sample size has also reported the use of endovascular 
therapy for the treatment of tandem lesions.22
Chronic carotid artery occlusion
Patients with symptomatic chronic carotid artery occlusion 
and haemodynamic cerebral ischaemia are at high risk 
for subsequent stroke when treated medically.23 However, 
the Carotid Occlusion Surgery Study (COSS) showed that 
EC- IC bypass surgery plus medical therapy compared with 
medical therapy alone did not reduce the risk of recurrent 
ipsilateral ischaemic stroke at 2 years. Medical treatment 
continues to be the current standard of care for carotid 
occlusion. Recently, emerging small sample studies have 
demonstrated the efficacy of reopening of chronically 
occluded carotid artery.24–26 These studies indicate that 
the reopening of chronic carotid artery occlusion may be 
effective for patients with chronic carotid artery occlu-
sion. However, randomised clinical trials are required 
to confirm the safety and benefit. In addition to treating 
culprit artery, contralateral CEA has been reported in 
patients with carotid occlusion and compromised cere-
bral haemodynamic reserve.27
Some other reported factors include type of symptoms 
(TIA, minor or major stroke; ocular or hemispheric symp-
toms), time since last symptomatic event and recurrence 
of symptoms.28
medICAl mAnAGemenT
Patients with ECAD can benefit from OMT consisting of 
antiplatelet agents, stains, and risk factor control.29
(1) Antiplatelet agents: although the benefit of single 
antiplatelet agent for stroke prevention in asymptom-
atic carotid stenosis has not been confirmed by RCTs,30 
current guidelines recommend lifelong low- dose aspirin 
as part of OMT to reduce the risk of stroke and other 
cardiovascular events.15 Dual antiplatelet therapy has 
been recommended during the periprocedural period 
and for at least 1 month after CAS.31
(2) Statins: statins have been routinely used in RCTs 
and clinical settings. A meta- analysis of 26 studies 
reported efficacy of statin with a dose- dependent protec-
tive effect,32 which was consistent with findings from 2 
RCTs done afterwards.33 34
(3) Risk factor control: hypertension is an important 
risk factor for ECAD, and the goal of blood pressure 
(BP) in non- diabetic patients with asymptomatic carotid 
stenosis is recommended below 140/90 mm Hg.35 Patients 
with concomitant diabetes are at particularly increased 
risk of cerebrovascular events, for whom a diastolic BP 
≤85 mm Hg has been recommended by the latest ESC 
guidelines.15
Previous studies have shown up to 26% risk of ipsilat-
eral ischaemic stroke over 2 years in patients with symp-
tomatic severe carotid artery stenosis despite OMT.5 It is 
therefore pivotal to consider more effective intervention.
InTervenTIonAl mAnAGemenT
Interventional management consisting mainly of CEA 
and CAS has been shown to decrease the stroke rate in 
patients with carotid artery stenosis.3 24 25 31–35
Carotid endarterectomy
ECST, NASCET and VA309 (Veterans Affairs 309) trials 
have demonstrated significant benefit of surgical interven-
tion over medical treatment for secondary stroke preven-
tion in patients with ipsilateral 50%–99% symptomatic 
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Table 1 RCTs to compare CEA and CAS for carotid stenosis
Trial Study population Follow- up Primary endpoint Results
WALLSTENT56 Symptomatic stenosis 
of 60%–99%
(n=219)
24 hours;
1, 6, 12 months
Ipsilateral stroke, or 
death within 1 year
CAS with significantly higher primary endpoint 
(12.1% vs 3.6%, p=0.022)
No significant difference in any major stroke at 
1 year (3.7% vs 0.9%, p=0.204)
CAS with significantly higher complication rates at 
30 days (12.1% vs 4.5%, p=0.049)
CAVATAS43 55 Carotid stenosis 
equally suitable for 
CAS and CEA
(n=504)
Median 5 years Any stroke or death No significant difference for disabling stroke or 
death within 30 days (6.4% vs 5.9%)
CAS with significantly more severe restenosis after 
1- y (14% vs 4%, p<0.001)
CAS with higher 8- y rate of ipsilateral (11.3% vs 
8.6%) & any stroke (21.1% vs 15.4%)
SAPPHIRE46 47 Symptomatic: >50%;
Asymptomatic: >80%;
(n=334)
30 days; 1, 2, 3 
years
Death, stroke, or MI 
within 30 days; death 
or ipsilateral stroke 
beyond 30 days
Lower primary endpoint with CAS (12.2% vs 
20.1%) (p=0.053)
Less carotid revascularisation with CAS at 1 year 
(0.6% vs 4.3%, p=0.04)
No significant difference in outcome at 3 years 
(24.6% vs 26.9%)
EVA- 3S50 51 Symptomatic carotid 
stenosis of ≥60%
(n=527)
Median 7.1 years Composite of any 
stroke or death within 
30 days
Significantly higher rate of any stroke or death with 
CAS within 30 days (9.6% vs 3.9%), at 6 months 
(11.7% vs 6.1%), and 5 years (11.0% vs 6.3%)
No significant difference in any stroke or death at 
10 years (11.5% vs 7.6%, p=0.07)
SPACE48 49 Symptomatic severe 
carotid stenosis
(n=1200)
1, 7, 30 days; 6, 
12, 24 months
ipsilateral ischaemic 
stroke or death within 
30 days
Primary endpoint: CAS 6.84% vs CEA 6.34% 
(p=0.09 for non- inferiority)
No significant difference in ipsilateral ischaemic 
stroke and periprocedural stroke or death at 2 years 
(CAS 9.5% vs CEA 8.8%)
Significantly higher rate of restenosis with CAS 
(10.4% vs 4.6%, p=0.009)
CREST44 45 Symptomatic:
>50% on 
angiography,
>70% on CTA, MRA 
or US
Asymptomatic:
>60% on 
angiography,
>70% on US,
>80% on CTA or MRA
(n=2502)
Median 2.5 
years; 10 years
composite of stroke, 
MI or death during 
periprocedural period 
or ipsilateral stroke 
within 4 years after 
randomisation
No significant difference in primary endpoint: CAS 
7.2% vs CEA 6.8% (p=0.51)
Similar in periprocedural death: CAS 0.7% vs CEA 
0.3% (p=0.18)
Significantly more periprocedural stroke in CAS 
(4.1% vs 2.3%, p=0.01)
Significantly more MI in CEA (2.3% vs 1.1%, 
p=0.03);
No significant difference in primary endpoint at 10 
years (CEA 9.9% vs CAS 11.8%)
No significant difference in postprocedural stroke at 
10 years (CEA 5.6% vs CAS 6.9%)
ICSS52 53 Symptomatic carotid 
stenosis of more than 
50%
(n=1713)
Median 4.2 years 3 year rate of fatal or 
disabling stroke in any 
territory
No significant difference in disabling stroke or death 
at 120 days (4.0% vs 3.2%)
Higher incidence of stroke, death or procedural MI 
with CAS at 120 days (8.5% vs 5.2%, p=0.006)
Higher risk of stroke (HR, 1.92) and all- cause death 
(HR, 2.76) with CAS at 120 days
Similar 5 year risk of fatal or disabling stroke (6.4% 
vs 6.5%)
Higher rate of any stroke at 5 years with CAS 
(15.2% vs 9.4%, p<0.001)
No significant difference in mRS at 1 year, 5 years 
and final follow- up
Continued
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Trial Study population Follow- up Primary endpoint Results
ACT-154 Asymptomatic severe 
carotid stenosis
(n=1453)
5 years Composite of death, 
stroke, or MI within 
30 days or ipsilateral 
stroke within 1 year
No significant difference in primary endpoint (3.8% 
vs 3.4%)
No significant difference in stroke or death within 30 
days (2.9% vs 1.7%, p=0.33)
No significant difference in ipsilateral stroke (2.2% 
vs 2.7%, p=0.51) and overall survival rate (87.1% vs 
89.4%, p=0.21) from 30 days to 5 years
Similar cumulative 5 year rate of stroke- free survival 
(93.1% vs 94.7%, p=0.44)
CAS, carotid artery stenting; CEA, carotid endarterectomy; CTA, CT angiography; MI, myocardial infarction;MRA, magnetic resonance 
angiography; mRS, modified Rankin Scale; RCT, randomised controlled trial; US, ultrasonography.
Table 1 Continued
carotid artery stenosis, with maximal efficacy in patients 
with 70%–99% carotid stenosis.3 36 37 Of note, pooled anal-
ysis of these trials showed no benefit of CEA for patients 
with 0%–49% stenosis.7
For asymptomatic carotid stenosis, ACAS (Asymptom-
atic Carotid Atherosclerosis Study) and ACST-1 (Asymp-
tomatic Carotid Surgery Trial) established the benefit 
of CEA over medical therapy alone in patients with 
60%–99% carotid stenosis.38 39 However, both studies 
started before the era of modern OMT, the widespread use 
of which has reduced the annual stroke rate significantly 
since the 1990s.40 In ACST-1, for example, the percentage 
of statin use has increased from 10% in the early period 
of recruitment to 80% by the end of follow- up.41 As such, 
it may be reasonable to consider OMT first for some 
patients who were considered surgical candidates in the 
past.
CeA versus CAs
CEA was first described in 1975 by DeBakey and has since 
become a conventional treatment for severe ECAD.42 
As an alternative to CEA, CAS emerged in 1989 and has 
proven to be effective and safe for carotid artery stenosis. 
A number of RCTs have been done to compare the two 
interventional therapies (table 1).43–58 Most studies have 
shown a higher rate of periprocedural stroke from CAS 
and a higher incidence of myocardial infarction (MI) 
with CEA. Similar findings have also been reported by a 
Cochrane review of 7572 patients, including 16 trials in 
2012,59 and a meta- analysis of 6526 patients from 5 RCTs 
in 2017.60 Similar long- term outcomes, including the rate 
of ipsilateral ischaemic stroke or death with CAS and 
CEA, have been reported by most of the studies. CEA is 
preferable to CAS in patients over 70 years old.9
CurrenT GuIdelInes
The guideline recommendations for the management 
of symptomatic and asymptomatic carotid artery stenosis 
are listed in the online supplementary table. In general, 
current guidelines recommend OMT as an essential 
treatment for all patients with carotid artery stenosis, 
whereas symptomatic patients with >50% stenosis and 
highly selected asymptomatic patients with >60% stenosis 
be considered for additional interventional manage-
ment if the estimated periprocedural complication rate 
is <3%.50–52 The choice between CEA and CAS should 
be made after considering demographics (eg, age and 
gender), anatomic, clinical (eg, contralateral TIA/stroke) 
and imaging (ipsilateral silent infarction, stenosis progres-
sion, spontaneous embolisation on transcranial Doppler, 
impaired cerebral vascular reserve, large plaques and so 
on) features.2 50 51
fuTure dIreCTIon
Due to significant advances in medical therapy, risk 
reduction and endovascular technology in recent years, 
there is renewed discussion regarding the superiority of 
CEA over CAS and interventional management over the 
best medical therapy, especially in asymptomatic carotid 
stenosis. Several studies are being conducted to address 
these issues.
ACST-2 is an RCT comparing immediate and long- term 
safety and efficacy of CEA versus CAS in a patient with 
severe asymptomatic stenosis.61 The primary endpoint 
is 30- day MI, stroke and death, with subgroup analysis 
emphasising health economic aspects including proce-
dural and stroke- related healthcare costs and quality of 
life. This study is recruiting patients from over 20 coun-
tries currently with 3600 patients planned to be enrolled 
by 2019.
SPACE 2 is a three- arm RCT designed to compare 
current OMT with CAS and CEA in addition to conser-
vative treatments in patients with asymptomatic carotid 
artery stenosis. The study was halted after enrolling 513 
patients. The 30- day rate of stroke/death was 2.54%, 
1.97% and 0% in CAS, CEA and OMT groups, respec-
tively.62 63
CREST-2 is an undergoing three- arm RCT to compare 
current OMT, OMT plus CEA, and OMT plus CAS for 
asymptomatic severe carotid stenosis, which enables a 
direct comparison of CAS and CEA. The primary endpoint 
is any stroke/death within 44 days after randomisation or 
ipsilateral ischaemic stroke within 4 years. This study is 
estimated to be completed by 2020.64
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ECST-2 (ISRCTN 97744893) is an international RCT 
aimed to investigate the optimal treatment in patients 
with symptomatic or asymptomatic moderate or severe 
carotid stenosis at low or intermediate risk of stroke, in 
which patients will be randomised to OMT versus CAS or 
CEA. The primary endpoint is any stoke at any time or 
non- stroke death within 30 days after surgery. This trial is 
currently recruiting participants and estimated and esti-
mated to be completed by 2022.
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